anti-NY-ESO-1 TCR T-cell therapy (Shenzhen BinDeBio)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-NY-ESO-1 TCR T-cell therapy (Shenzhen BinDeBio)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionHuman leukocyte antigen modulatorsCancer/testis antigen 1 modulators

TargetsCancer/testis antigen 1Human leukocyte antigen

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaClinical

Originator CompaniesShenzhen Bindebio Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Bindebio Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A